These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3625298)

  • 1. Generator-produced yttrium-90 for radioimmunotherapy.
    Chinol M; Hnatowich DJ
    J Nucl Med; 1987 Sep; 28(9):1465-70. PubMed ID: 3625298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of radiolysis on yttrium-90-labeled Lym-1 antibody preparations.
    Salako QA; O'Donnell RT; DeNardo SJ
    J Nucl Med; 1998 Apr; 39(4):667-70. PubMed ID: 9544679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DTPA-coupled antibodies labeled with yttrium-90.
    Hnatowich DJ; Virzi F; Doherty PW
    J Nucl Med; 1985 May; 26(5):503-9. PubMed ID: 3989606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study.
    Riva P; Franceschi G; Frattarelli M; Lazzari S; Riva N; Giuliani G; Casi M; Sarti G; Guiducci G; Giorgetti G; Gentile R; Santimaria M; Jermann E; Maeke HR
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3275s-3280s. PubMed ID: 10541375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.
    Govindan SV; Shih LB; Goldenberg DM; Sharkey RM; Karacay H; Donnelly JE; Losman MJ; Hansen HJ; Griffiths GL
    Bioconjug Chem; 1998; 9(6):773-82. PubMed ID: 9815172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution.
    Carrasquillo JA; White JD; Paik CH; Raubitschek A; Le N; Rotman M; Brechbiel MW; Gansow OA; Top LE; Perentesis P; Reynolds JC; Nelson DL; Waldmann TA
    J Nucl Med; 1999 Feb; 40(2):268-76. PubMed ID: 10025834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
    Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of radiolysis of monoclonal antibody during labeling.
    Chakrabarti MC; Le N; Paik CH; De Graff WG; Carrasquillo JA
    J Nucl Med; 1996 Aug; 37(8):1384-8. PubMed ID: 8708780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
    Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid determination of (90)Sr impurities in freshly "generator eluted"(90)Y for radiopharmaceutical preparation.
    Bonardi ML; Martano L; Groppi F; Chinol M
    Appl Radiat Isot; 2009 Oct; 67(10):1874-7. PubMed ID: 19628401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy.
    Kosmas C; Maraveyas A; Gooden CS; Snook D; Epenetos AA
    J Nucl Med; 1995 May; 36(5):746-53. PubMed ID: 7738643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemistry for commercial scale production of yttrium-90 for medical research.
    Wike JS; Guyer CE; Ramey DW; Phillips BP
    Int J Rad Appl Instrum A; 1990; 41(9):861-5. PubMed ID: 2176193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Processing of generator-produced 68Ga for medical application.
    Zhernosekov KP; Filosofov DV; Baum RP; Aschoff P; Bihl H; Razbash AA; Jahn M; Jennewein M; Rösch F
    J Nucl Med; 2007 Oct; 48(10):1741-8. PubMed ID: 17873136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.
    Richman CM; DeNardo SJ; O'Donnell RT; Goldstein DS; Shen S; Kukis DL; Kroger LA; Yuan A; Boniface GR; Griffith IJ; DeNardo GL
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3243s-3248s. PubMed ID: 10541370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice.
    Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM
    J Nucl Med; 1998 Mar; 39(3):476-84. PubMed ID: 9529295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the Oak Ridge National Laboratory tungsten-188/rhenium-188 generator for preparation of the rhenium-188 HDD/lipiodol complex for trans-arterial liver cancer therapy.
    Jeong JM; Knapp FF
    Semin Nucl Med; 2008 Mar; 38(2):S19-29. PubMed ID: 18243839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.